Direkt zum Inhalt
Merck

Topical administration of tranexamic acid in primary total hip and total knee arthroplasty.

The Journal of arthroplasty (2013-11-19)
Joseph G Martin, Kevin B Cassatt, Katie A Kincaid-Cinnamon, Denise S Westendorf, Ann S Garton, Jon H Lemke
ZUSAMMENFASSUNG

Major blood loss is a known potential complication in total hip and total knee arthroplasty. We conducted a prospective, stratified, randomized, double-blind, placebo-controlled trial that evaluated 100 patients undergoing total knee or total hip arthroplasty to evaluate the effect on blood loss using the topical application of tranexamic acid. Participants received either 2 g of topical tranexamic acid or the equivalent volume of placebo into the joint prior to surgical closure. Tranexamic acid resulted in a lower mean maximum decline in postoperative hemoglobin levels when compared to placebo (P = 0.013). Patients in the tranexamic acid group demonstrated an improved but non-significant reduction in the units of blood transfused compared to placebo (P = 0.423). There was no clinically significant increase in complications in the tranexamic acid group, including no incidence of venous thromboembolism.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Trans-4-(Aminomethyl)cyclohexancarboxylsäure, 97%
USP
Tranexamsäure, United States Pharmacopeia (USP) Reference Standard
Tranexamsäure, European Pharmacopoeia (EP) Reference Standard